

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Arkin Bio Ventures 2 L.P.</u> (Last) (First) (Middle) 6 HACHOSHLIM STREET (Street) HERZLIYA L3 4672406 PITUACH (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Werewolf Therapeutics, Inc. [HOWL]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 05/04/2021	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	05/04/2021		C		1,235,917	A	(1)	1,235,917	I	See footnote ⁽²⁾
Common Stock	05/04/2021		C		410,717	A	(3)	1,646,634	I	See footnote ⁽²⁾
Common Stock	05/04/2021		P		400,000	A	\$16	2,046,634	I	See footnote ⁽²⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					
Series A Preferred Stock	(1)	05/04/2021		C		10,714,284	(1)	(1)	Common Stock	1,235,917	\$0.00	0	I	See footnote ⁽²⁾
Series B Preferred Stock	(3)	05/04/2021		C		3,560,551	(3)	(3)	Common Stock	410,717	\$0.00	0	I	See footnote ⁽²⁾

1. Name and Address of Reporting Person*
Arkin Bio Ventures 2 L.P.
 (Last) (First) (Middle)
 6 HACHOSHLIM STREET
 (Street)
 HERZLIYA L3 4672406
 PITUACH
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
Arkin Bio Ventures GPGP Ltd.
 (Last) (First) (Middle)
 6 HACHOSHLIM STREET
 BUILDING C
 (Street)
 HERZLIYA L3 4672406
 PITUACH
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
Arkin Moshe

(Last)	(First)	(Middle)
6 HACHOSHLIM ST.		
<hr/>		
(Street)		
HERZELIA	L3	4672406
<hr/>		
(City)	(State)	(Zip)

Explanation of Responses:

1. On May 4, 2021, the Series A Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
2. The securities are held by Arkin Bio Ventures 2 L.P. (the "Fund"). The general partner of the Fund is Arkin Bio Ventures GP, the general partner of which is Arkin Bio Ventures GPGP Ltd. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Ventures GPGP Ltd. As a result, each of Arkin Bio Ventures GP, Arkin Bio Ventures GPGP Ltd. and Mr. Arkin may be deemed to share voting and investment power with respect to the shares held by the Fund.
3. On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.

Remarks:

This Form 4 shall not be construed as an admission by any of the Reporting Persons or any other entity named in this Form 4 that it is the beneficial owner of any of the securities covered by this Form 4, and each such Reporting Person or entity disclaims beneficial ownership of any such securities, except to the extent of its pecuniary interest therein.

Arkin Bio Ventures 2 L.P., By:
Its ultimate General Partner,
Arkin Bio Ventures GPGP Ltd.,
By: Its sole shareholder and 05/04/2021
Chairman of the Board, Moshe
Arkin, By: /s/ Yair Ben Yosef,
attorney-in-fact

Arkin Bio Ventures GPGP Ltd.,
By: Its sole shareholder and
Chairman of the Board, Moshe 05/04/2021
Arkin, By: /s/ Yair Ben Yosef,
attorney-in-fact

Moshe Arkin, By: /s/ Yair Ben
Yosef, attorney-in-fact 05/04/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.